Dataset Changes Helpnotes 2017 Question No Question Answer Options Guidance/Definition 2.1.7 Was the patient on anticoagulant Yes Yes is available even if patient is not in AF prior to this admission. No medication prior to admission? No but To select but’ in answer to this question that it is recorded that a ‘No prescriber judged the patient’s risk of a bleeding complication to outweigh the benefit in stroke risk reduction. If this cannot be confirmed then the answer to this question is ‘No’. Anticoagulation refers to treatment with an anticoagulant: Vitamin K antagonists: Warfarin and Phenindione DOAC = Direct Oral Anticoagulant: Apixaban (Eliquis), Rivaroxaban (Xarelto) and Dabigatran (Pradaxa), Edoxaban (Lixiana). Heparin = Includes treatment dose unfractionated heparin and Low Molecular Weight Heparin Anticoagulation does not refer to treatment with aspirin, clopidogrel or another antiplatelet agent. 2.1.7(a) What anticoagulation was the Vitamin K antagonist Available if 2.1.7 = Select all that apply. ‘Yes’. (includes Warfarin) patient prescribed before their DOAC stroke? Vitamin K antagonists: Warfarin and Phenindione Heparin DOAC = Direct Oral Anticoagulant: Apixaban (Eliquis), Rivaroxaban (Xarelto) and Dabigatran (Pradaxa), Edoxaban (Lixiana). Heparin = Includes treatment dose unfractionated heparin and Low Molecular Weight Heparin 2.1.7(b) What was the patient’s International Value range: 0.0 Available if 2.1.7(a) = K antagonist’ – ‘Vitamin 10.00 Normalised ratio (INR) on arrival at INR not checked If inpatient, INR at the time of stroke should be used. hospital (if inpatient, INR at the time Greater than 10 of stroke onset)?
Dataset Changes Helpnotes 2017 Question No Question Answer Options Guidance/Definition 2.1.7 Was the patient on anticoagulant medication prior to admission? Yes No No but Yes is available even if patient is not in AF prior to this admission. To select ‘No but’ in answer to this question that it is recorded that a prescriber judged the patient’s risk of a bleeding complication to outweigh the benefit in stroke risk reduction. If this cannot be confirmed then the answer to this question is ‘No’. Anticoagulation refers to treatment with an anticoagulant: Vitamin K antagonists: Warfarin and Phenindione DOAC = Direct Oral Anticoagulant: Apixaban (Eliquis), Rivaroxaban (Xarelto) and Dabigatran (Pradaxa), Edoxaban (Lixiana). Heparin = Includes treatment dose unfractionated heparin and Low Molecular Weight Heparin Anticoagulation does not refer to treatment with aspirin, clopidogrel or another antiplatelet agent. 2.1.7(a) What anticoagulation was the patient prescribed before their stroke? Vitamin K antagonist (includes Warfarin) DOAC Heparin Available if 2.1.7 = ‘Yes’. Select all that apply. Vitamin K antagonists: Warfarin and Phenindione DOAC = Direct Oral Anticoagulant: Apixaban (Eliquis), Rivaroxaban (Xarelto) and Dabigatran (Pradaxa), Edoxaban (Lixiana). Heparin = Includes treatment dose unfractionated heparin and Low Molecular Weight Heparin 2.1.7(b) What was the patient’s International Normalised ratio (INR) on arrival at hospital (if inpatient, INR at the time of stroke onset)? Value range: 0.0 – 10.00 INR not checked Greater than 10 Available if 2.1.7(a) = ‘Vitamin K antagonist’ If inpatient, INR at the time of stroke should be used.
SSNAP_Dataset_Changes_Helpnotes_2017.docx